Navigation Links
RNA promotes metastasis in lung cancer
Date:2/5/2013

The vast majority approximately 80 percent of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

Long non-coding RNAs regulate cellular processes such as cell cycle, growth and cell death. Therefore, it came as no surprise that many of these controlling molecules are linked to the progression of cancer. An example is the non-coding RNA MALAT1, which is considered a marker for disease progression in various forms of lung cancer: "The more MALAT1 tumor cells produce, the higher the odds for metastasis and a very unfavorable course of the disease," says Dr. Sven Diederichs, who discovered the molecule as part of his doctoral thesis. Diederichs now leads a junior research group at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Institute of Pathology of Heidelberg University.

In his current project, Diederichs has investigated the actual mechanisms used by MALAT1 to interfere in cellular processes and to promote metastasis. Diederichs and his team recently developed a method for selectively silencing long non-coding RNAs in the cell. To do so, the researchers integrate signaling sequences into the DNA which cause RNA transcripts to be broken down immediately after being formed. Then they analyze resulting changes in cellular biology.

For the first time, Diederichs and his team have been able to achieve almost complete silencing of MALAT1 in lung cancer cell cultures. In the modified cells they found that MALAT1 regulates numerous genes involved in metastasis. As a result, MALAT1-deficient tumor cells have impaired mobility and are less capable of invading surrounding tissue. When implanted in mice, they formed considerably less tumor nodules in the animals' lungs than cancer cells with intact MALAT1.

Encouraged by this result, the investigators explored whether it is also possible to block MALAT1 and thus prevent metastasis in an intact organism. In collaboration with ISIS Pharmaceuticals, Inc., the Heidelberg scientists developed short nucleic acid strands (antisense oligonucleotides) which are taken up by the cells and specifically block RNA molecules.

In mice injected with human lung cancer cells, MALAT1-specific antisense strands successfully inhibited metastasis formation. The animals' lungs showed fewer and smaller tumor nodules than those of control animals that had not been given the substance.

"Ten years after we discovered MALAT1 as a predictive marker in lung cancer, we now understand how this non-coding RNA influences metastasis. Moreover, this RNA has turned out to be a potential target for an innovative treatment with antisense RNAs." Diederichs and his team will further investigate this promising approach aiming to eventually prevent lung cancer from spreading.


'/>"/>

Contact: Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. A blend of soy and dairy proteins promotes muscle protein synthesis when consumed after exercise
2. Cohen Children’s Medical Center of New York Promotes Brand and Wellness with Community Play Area Sponsorship
3. Hepatitis B virus promotes oncogenesis through microRNA modulation
4. Assure A Smile Promotes Oral Health Awareness in Miami with New Website
5. Blue Sky Systems, LLC Promotes Health through Supplements via Website and Blog
6. Smartphones: Artists Promotes Face-to-Face Conversation
7. The Hong Kong Polytechnic University promotes knowledge enterprises through MAKE Award
8. Smile Reef Pediatric Dentist Promotes Dental Care for Kids During the Holidays
9. Alcoholics Anonymous participation promotes long-term recovery
10. Scientists discover mechanism that promotes lung cancer growth and survival
11. RANK protein promotes the initiation, progression and metastasis of human breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, ... prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , ... as the visionary leader in the training of physicians, scientists, and members of ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wall Centre Dental team is ... from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain veneers, ... esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton Reskovich ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... Mich. (PRWEB) , ... March ... ... and Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, ... supplement industry. The organization, which plans to publish the first ANSI-approved GMP ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices has recently updated its ... equipment shapes for free and download shapes and stencils from http://www.VisioStencils.com. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Maxor National Pharmacy Services, LLC ("Maxor"), ... has named Leah Bailey as General Counsel.  Bailey ... the company. With more than 13 years ... years focused on health care, Bailey joins the Maxor ... Prime, Bailey advised the PBM, Specialty, and Mail Order ...
(Date:3/29/2017)... 2017 Varian Medical Systems (NYSE: VAR ... second quarter of fiscal year 2017 following the close of ... will be followed by a teleconference available to all interested ... link to the conference call webcast will be available on ... teleconference call and replay: ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
Breaking Medicine Technology: